TipRanks
Eli Lilly & Co (DE:LLY)
XETRA:LLY
Germany Market
LLY
Eli Lilly & Co
RESEARCH TOOLSreports

Eli Lilly & Co (LLY) Stock Forecast & Price Target

209 Followers
See the Price Targets and Ratings of:

LLY Analyst Ratings

Strong Buy
23Ratings
Strong Buy
20 Buy
2 Hold
1 Sell
Based on 23 analysts giving stock ratings to
Eli
Lilly & Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

€1,216.74
▲(20.35% Upside)
Based on 23 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is €1,216.74 with a high forecast of €1,425.12 and a low forecast of €837.26. The average price target represents a 20.35% change from the last price of €1,011.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"686":"€686","871":"€871","1056":"€1,056","1241":"€1,241","1426":"€1,426"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1425.119328,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.43K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1216.740161259,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.22K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":837.2576052000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€837.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[686,871,1056,1241,1426],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1023.2,1054.1168713846155,1085.033742769231,1115.9506141538461,1146.8674855384616,1177.784356923077,1208.7012283076924,1239.6180996923076,1270.534971076923,1301.4518424615385,1332.368713846154,1363.2855852307694,1394.2024566153846,{"y":1425.119328,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1023.2,1038.0877047122308,1052.9754094244615,1067.8631141366923,1082.750818848923,1097.6385235611538,1112.5262282733847,1127.4139329856155,1142.3016376978462,1157.189342410077,1172.0770471223077,1186.9647518345384,1201.8524565467692,{"y":1216.740161259,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1023.2,1008.8967388615386,994.593477723077,980.2902165846155,965.9869554461538,951.6836943076923,937.3804331692309,923.0771720307692,908.7739108923078,894.4706497538461,880.1673886153847,865.8641274769232,851.5608663384616,{"y":837.2576052000001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":687.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":738.149,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":913.988,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":912.197,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":887.914,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":881.326,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":820.917,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":785.229,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":921.503,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 87,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1044.929,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":992.603,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1015.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1023.2,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€1,425Average Price Target€1,217Lowest Price Target€837.26
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:LLY
Jason Gerberry
Bank of America Securities
Bank of America Securities
€1,197.1→€1,194.43
Buy
18.14%
Upside
Reiterated
10/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NYSE: NVST), Bristol-Myers Squibb (NYSE: BMY) and Eli Lilly & Co (NYSE: LLY)
Morgan Stanley Analyst forecast on DE:LLY
Terence Flynn
Morgan Stanley
Morgan Stanley
€1,273.7
Buy
25.98%
Upside
Reiterated
10/09/26
Morgan Stanley Releases a Buy Rating on Eli Lilly & Co (LLY)
J.P. Morgan Analyst forecast on DE:LLY
Chris Schott
J.P. Morgan
J.P. Morgan
€1,336.05
Buy
32.15%
Upside
Reiterated
10/09/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Legend Biotech (NASDAQ: LEGN) and Bristol-Myers Squibb (NYSE: BMY)
Cantor Fitzgerald Analyst forecast on DE:LLY
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€1,255.89→€1,282.61
Buy
26.87%
Upside
Assigned
10/08/26
Eli Lilly & Co (LLY) Receives a Buy from Cantor Fitzgerald
Barclays Analyst forecast on DE:LLY
Emily Field
Barclays
Barclays
€1,246.98
Buy
23.34%
Upside
Reiterated
10/05/26
Analysts Are Bullish on Top Healthcare Stocks: Lifestance Health Group (LFST), Eli Lilly & Co (LLY)
Truist Financial Analyst forecast on DE:LLY
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
10/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Eli Lilly & Co (NYSE: LLY) and Liquidia Technologies (NASDAQ: LQDA)
RBC Capital Analyst forecast on DE:LLY
Trung Huynh
RBC Capital
RBC Capital
€1,336.05
Buy
32.15%
Upside
Reiterated
10/01/26
Eli Lilly & Co (LLY) Gets a Buy from RBC Capital
TD Cowen Analyst forecast on DE:LLY
Steve Scala
TD Cowen
TD Cowen
€1,113.37
Buy
10.13%
Upside
Reiterated
10/01/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Jade Biosciences (NASDAQ: JBIO)
BMO Capital Analyst forecast on DE:LLY
Evan Seigerman
BMO Capital
BMO Capital
€1,246.98
Buy
23.34%
Upside
Reiterated
09/30/26
Evan Seigerman Reiterates Buy on Eli Lilly, Citing Strong Obesity/Diabetes Portfolio and Pipeline Momentum, Maintains $1400 Price Target
Goldman Sachs Analyst forecast on DE:LLY
Asad Haider
Goldman Sachs
Goldman Sachs
€1,217.59→€1,221.15
Buy
20.79%
Upside
Reiterated
09/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Eli Lilly & Co (NYSE: LLY)
Evercore ISI Analyst forecast on DE:LLY
Umer Raffat
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
09/23/26
Analysts Conflicted on These Healthcare Names: TriSalus Life Sciences (NASDAQ: TLSI) and Eli Lilly & Co (NYSE: LLY)
JLPascual Analyst forecast on DE:LLY
Jose Luis Pascual
JLPascual
JLPascual
€921.87
Hold
-8.82%
Downside
Reiterated
09/23/26
Jefferies Analyst forecast on DE:LLY
Akash Tewari
Jefferies
Jefferies
€1,282.61
Buy
26.87%
Upside
Reiterated
09/22/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS), Moderna (NASDAQ: MRNA) and Eli Lilly & Co (NYSE: LLY)
Wells Fargo Analyst forecast on DE:LLY
Mohit Bansal
Wells Fargo
Wells Fargo
€1,184.63
Buy
17.17%
Upside
Reiterated
09/21/26
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (NASDAQ: ABVX) and Eli Lilly & Co (NYSE: LLY)
Guggenheim Analyst forecast on DE:LLY
Seamus Fernandez
Guggenheim
Guggenheim
€1,133.86→€1,143.66
Buy
13.12%
Upside
Reiterated
09/17/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:LLY
Jason Gerberry
Bank of America Securities
Bank of America Securities
€1,197.1→€1,194.43
Buy
18.14%
Upside
Reiterated
10/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NYSE: NVST), Bristol-Myers Squibb (NYSE: BMY) and Eli Lilly & Co (NYSE: LLY)
Morgan Stanley Analyst forecast on DE:LLY
Terence Flynn
Morgan Stanley
Morgan Stanley
€1,273.7
Buy
25.98%
Upside
Reiterated
10/09/26
Morgan Stanley Releases a Buy Rating on Eli Lilly & Co (LLY)
J.P. Morgan Analyst forecast on DE:LLY
Chris Schott
J.P. Morgan
J.P. Morgan
€1,336.05
Buy
32.15%
Upside
Reiterated
10/09/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Legend Biotech (NASDAQ: LEGN) and Bristol-Myers Squibb (NYSE: BMY)
Cantor Fitzgerald Analyst forecast on DE:LLY
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€1,255.89→€1,282.61
Buy
26.87%
Upside
Assigned
10/08/26
Eli Lilly & Co (LLY) Receives a Buy from Cantor Fitzgerald
Barclays Analyst forecast on DE:LLY
Emily Field
Barclays
Barclays
€1,246.98
Buy
23.34%
Upside
Reiterated
10/05/26
Analysts Are Bullish on Top Healthcare Stocks: Lifestance Health Group (LFST), Eli Lilly & Co (LLY)
Truist Financial Analyst forecast on DE:LLY
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
10/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Eli Lilly & Co (NYSE: LLY) and Liquidia Technologies (NASDAQ: LQDA)
RBC Capital Analyst forecast on DE:LLY
Trung Huynh
RBC Capital
RBC Capital
€1,336.05
Buy
32.15%
Upside
Reiterated
10/01/26
Eli Lilly & Co (LLY) Gets a Buy from RBC Capital
TD Cowen Analyst forecast on DE:LLY
Steve Scala
TD Cowen
TD Cowen
€1,113.37
Buy
10.13%
Upside
Reiterated
10/01/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Jade Biosciences (NASDAQ: JBIO)
BMO Capital Analyst forecast on DE:LLY
Evan Seigerman
BMO Capital
BMO Capital
€1,246.98
Buy
23.34%
Upside
Reiterated
09/30/26
Evan Seigerman Reiterates Buy on Eli Lilly, Citing Strong Obesity/Diabetes Portfolio and Pipeline Momentum, Maintains $1400 Price Target
Goldman Sachs Analyst forecast on DE:LLY
Asad Haider
Goldman Sachs
Goldman Sachs
€1,217.59→€1,221.15
Buy
20.79%
Upside
Reiterated
09/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Eli Lilly & Co (NYSE: LLY)
Evercore ISI Analyst forecast on DE:LLY
Umer Raffat
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
09/23/26
Analysts Conflicted on These Healthcare Names: TriSalus Life Sciences (NASDAQ: TLSI) and Eli Lilly & Co (NYSE: LLY)
JLPascual Analyst forecast on DE:LLY
Jose Luis Pascual
JLPascual
JLPascual
€921.87
Hold
-8.82%
Downside
Reiterated
09/23/26
Jefferies Analyst forecast on DE:LLY
Akash Tewari
Jefferies
Jefferies
€1,282.61
Buy
26.87%
Upside
Reiterated
09/22/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS), Moderna (NASDAQ: MRNA) and Eli Lilly & Co (NYSE: LLY)
Wells Fargo Analyst forecast on DE:LLY
Mohit Bansal
Wells Fargo
Wells Fargo
€1,184.63
Buy
17.17%
Upside
Reiterated
09/21/26
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (NASDAQ: ABVX) and Eli Lilly & Co (NYSE: LLY)
Guggenheim Analyst forecast on DE:LLY
Seamus Fernandez
Guggenheim
Guggenheim
€1,133.86→€1,143.66
Buy
13.12%
Upside
Reiterated
09/17/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
HELPHelus Pharma
ARDXArdelyx
CELCCelcuity
OMCLOmnicell
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months
Louise ChenScotiabank
Success Rate
28/37 ratings generated profit
76%
Average Return
+9.52%
Copying Louise Chen's trades and holding each position for 3 Months would result in 75.68% of your transactions generating a profit, with an average return of +9.52% per trade.
1 Year
Geoff MeachamCiti
Success Rate
43/44 ratings generated profit
98%
Average Return
+42.22%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 97.73% of your transactions generating a profit, with an average return of +42.22% per trade.
2 Years
Geoff MeachamCiti
Success Rate
44/44 ratings generated profit
100%
Average Return
+65.19%
Copying Geoff Meacham's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +65.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
3
2
0
0
0
Buy
84
76
70
66
50
Hold
3
3
4
5
4
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
90
81
74
72
55
In the current month, LLY has received 50 Buy Ratings, 4 Hold Ratings, and 1 Sell Ratings. LLY average Analyst price target in the past 3 months is 1,216.74.
Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is €8.87 with a range of €8.38 to €10.07. The previous quarter’s EPS was €7.46. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.
Next quarter’s earnings estimate for LLY is €8.87 with a range of €8.38 to €10.07. The previous quarter’s EPS was €7.46. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is €19.86B with a range of €19.05B to €21.41B. The previous quarter’s sales results were €20.46B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.
Next quarter’s sales forecast for LLY is €19.86B with a range of €19.05B to €21.41B. The previous quarter’s sales results were €20.46B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Stock Forecast FAQ

What is DE:LLY’s average 12-month price target, according to analysts?
Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 1,216.74.
    What is DE:LLY’s upside potential, based on the analysts’ average price target?
    Eli Lilly & Co has 20.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Eli Lilly & Co a Buy, Sell or Hold?
          Eli Lilly & Co has a consensus rating of Strong Buy, which is based on 20 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Eli Lilly & Co’s share price target?
            The average share price target for Eli Lilly & Co is 1,216.74. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €1,425.12 ,and the lowest forecast is €837.26. The average share price target represents 20.35% Increase from the current price of €1,011.
              What do analysts say about Eli Lilly & Co?
              Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of Eli Lilly & Co?
                To buy shares of DE:LLY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.